Age | Hoelen et al30 | Kralinger et al15 | Robinson et al11 | teSlaa et al3 | Sachs et al8 | Simonet and Cofield16 | Vermeiren et al31 | Safran et al32 | Pevny et al29 | Salomonsson et al28 | Total | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No recurrence (%) | ≥1 recurrent episode (%) | No recurrence | ≥1 recurrent episode | No recurrence (%) | ≥1 recurrent episode (%) | No recurrence | ≥1 recurrent episode | No recurrence | ≥1 recurrent episode | No recurrence | ≥1 recurrent episode | No recurrence (%) | ≥1 recurrent episode (%) | No recurrence (%) | ≥1 recurrent episode (%) | No recurrence (%) | ≥1 recurrent episode (%) | No recurrence (%) | ≥1 recurrent episode (%)e | No recurrence | ≥1 recurrent episode | |
15–20 | 35 | 65 | 13–20 years | 51 | 49 | 11–20 years | 12–20 years | 14–20 years | 46 | 54 | 54 | 46 | 17 | 83 | 337 | 266 | ||||||
21–30 | 37 | 63 | 39% | 61 | 71 | 29 | 63% | 37% | 60 | 40 | ||||||||||||
31–40 | 74 | 26 | 65% | 35 | 79 | 21 | 88 | 12 | 67 | 33 | ||||||||||||
41–50 | 100 | 0 | 89% | 11% | 94% | 6% | 90% | 10 | 100 | 0 | 100 | 0 | 55 | 45 | 361 | 45 | ||||||
51–60 | 95 | 5 | 73% | 27% | 100 | 0 | ||||||||||||||||
61–70 | 90 | 10 | 86% | 14% | 91 | 33 | ||||||||||||||||
71–80 | 100 | 0 | 78% | 22% | 100 | 0 | ||||||||||||||||
80–100 | 100 | 0 | 73% | 27% | ||||||||||||||||||
Total | 74 | 26 | 76% | 30% | 65% | 35% | 80% | 20% | 90 | 10 | 70 | 20 | 75 | 25 | 54 | 46 | 96 | 4 | 47 | 53 | 698 | 311 |